Clinical Trial Update: L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating L-Annamycin for Injection in combination with cytarabine as second-line remission induction therapy for adults with ref…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cytarabine Injection (Cytarabine)
• L-Annamycin for Injection (L-Annamycin)

Snippet

Sponsor: Moleculin Biotech, Inc. | Conditions: Acute Myeloid Leukaemia (AML) | Phase 2, Phase 3 | Status: RECRUITING